These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22672791)

  • 21. Apparent inappropriate shocks from an implantable cardioverter defibrillator:
    Moore DR; Kok LC; Vijayaraman P
    J Cardiovasc Electrophysiol; 2004 Jan; 15(1):116-7. PubMed ID: 15028086
    [No Abstract]   [Full Text] [Related]  

  • 22. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
    Roston TM; Vinocur JM; Maginot KR; Mohammed S; Salerno JC; Etheridge SP; Cohen M; Hamilton RM; Pflaumer A; Kanter RJ; Potts JE; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Kannankeril PJ; Sanatani S
    Circ Arrhythm Electrophysiol; 2015 Jun; 8(3):633-42. PubMed ID: 25713214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ICD proarrhythmia as a consequence of an interaction with an algorithm to prevent atrial arrhythmias.
    Martínez-Sánchez J; García-Alberola A; Sánchez-Muñoz JJ; Peñafiel-Verdú P; Giner-Caro JA; Valdés-Chávarri M
    Pacing Clin Electrophysiol; 2009 Aug; 32(8):1096-8. PubMed ID: 19659632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Catecholaminergic polymorphic ventricular tachycardia.
    Leenhardt A; Denjoy I; Guicheney P
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):1044-52. PubMed ID: 23022705
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
    Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
    Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy.
    Patel C; Yan GX; Kocovic D; Kowey PR
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):705-11; discussion 712. PubMed ID: 20009081
    [No Abstract]   [Full Text] [Related]  

  • 27. Flecainide for recurrent malignant ventricular arrhythmias in two siblings with Andersen-Tawil syndrome.
    Bökenkamp R; Wilde AA; Schalij MJ; Blom NA
    Heart Rhythm; 2007 Apr; 4(4):508-11. PubMed ID: 17399642
    [No Abstract]   [Full Text] [Related]  

  • 28. Non-determinable defibrillation threshold and inefficacy of implantable cardioverter/defibrillator shocks due to defective connections of the defibrillator lead terminals in the device header port.
    Maagh P; Trappe HJ; Meissner A
    Europace; 2007 Dec; 9(12):1161-2. PubMed ID: 17913694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ventricular arrhythmias in patients with implanted cardioverter defibrillators.
    John RM; Stevenson WG
    Trends Cardiovasc Med; 2012 Oct; 22(7):169-73. PubMed ID: 22902094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
    Bergeman AT; Lieve KVV; Kallas D; Bos JM; Rosés I Noguer F; Denjoy I; Zorio E; Kammeraad JAE; Peltenburg PJ; Tobert K; Aiba T; Atallah J; Drago F; Batra AS; Brugada R; Borggrefe M; Clur SB; Cox MGPJ; Davis A; Dhillon S; Etheridge SP; Fischbach P; Franciosi S; Haugaa K; Horie M; Johnsrude C; Kane AM; Krause U; Kwok SY; LaPage MJ; Ohno S; Probst V; Roberts JD; Robyns T; Sacher F; Semsarian C; Skinner JR; Swan H; Tavacova T; Tisma-Dupanovic S; Tfelt-Hansen J; Yap SC; Kannankeril PJ; Leenhardt A; Till J; Sanatani S; Tanck MWT; Ackerman MJ; Wilde AAM; van der Werf C
    Circulation; 2023 Dec; 148(25):2029-2037. PubMed ID: 37886885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in the diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia.
    Roston TM; Cunningham TC; Sanatani S
    Cardiol Young; 2017 Jan; 27(S1):S49-S56. PubMed ID: 28084961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ventricular oversensing after replacement of an implantable cardioverter-defibrillator.
    Arias MA; Puchol A; Castellanos E; Pachón M; Rodríguez-Padial L
    Pacing Clin Electrophysiol; 2009 Jul; 32(7):925-7. PubMed ID: 19572871
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacological treatment of electrical storm in cathecolaminergic polymorphic ventricular tachycardia.
    Fagundes A; DE Magalhaes LP; Russo M; Xavier E
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):e27-31. PubMed ID: 19889187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
    Vaksmann G; Klug D
    Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of flecainide in a patient with catecholaminergic polymorphic ventricular tachycardia.
    Biernacka EK; Hoffman P
    Europace; 2011 Jan; 13(1):129-30. PubMed ID: 20798117
    [No Abstract]   [Full Text] [Related]  

  • 36. Catecholaminergic polymorphic ventricular tachycardia: a model for genotype-specific therapy.
    Roston TM; Van Petegem F; Sanatani S
    Curr Opin Cardiol; 2017 Jan; 32(1):78-85. PubMed ID: 27861184
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case report: Delayed detection of ventricular tachycardia due to intradevice interactions by implantable atrio-ventricular pacer/cardioverter defibrillator.
    Kantharia BK; Padder FA
    J Interv Card Electrophysiol; 2006 Aug; 16(2):135-8. PubMed ID: 17016683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Shocking truths about implantable cardioverter defibrillator monitoring zones.
    Mansour F; Thibault B; Dubuc M; Guerra PG; Macle L; Brugada R; Roy D; Talajic M; Khairy P
    Pacing Clin Electrophysiol; 2007 Sep; 30(9):1146-8. PubMed ID: 17725760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quinidine ceases electrical storm in an ablated patient with an implantable cardioverter-defibrillator: an old lady in the modern era.
    Georgiadou P; Iliodromitis EK; Theodorakis GN; Kremastinos DT
    Int J Cardiol; 2006 Oct; 113(1):129-31. PubMed ID: 16318889
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
    Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
    N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.